Gilead’s Coronavirus Therapy Remdesivir Beats Sales Estimates

(Bloomberg) -- Gilead Sciences Inc. reported $873 million in third-quarter sales of its coronavirus therapy Veklury, above analysts’ expectations, as the company transitions to commercial sales for...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.